In conclusion, this study has shown for the first time that the intestine-targeted delivery of the DGAT1 inhibitor improves postprandial hyperlipidemia, body adiposity, hepatic lipid accumulation and insulin resistance without skin aberrations. This evidence concerns the gene DGAT1 and hyperlipidemia.